Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
13 nov. 2023 16h05 HE
|
Biora Therapeutics, Inc.
NaviCap™ platform advancing toward initiation of phase 1 clinical trial by year end; Pharma collaborations accelerate for the BioJet™ platform
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
06 nov. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST
Biora Therapeutics Submits Updated IND Application for BT-600
30 oct. 2023 16h05 HE
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Biora Therapeutics to Submit Updated IND Application for BT-600
23 oct. 2023 17h30 HE
|
Biora Therapeutics, Inc.
Update to include supplemental information and allow additional time for regulatory review. Biora anticipates remaining on track with ph1 trial timeline.
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
05 oct. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
25 sept. 2023 08h00 HE
|
Biora Therapeutics, Inc.
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust...
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
19 sept. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 ...
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
11 sept. 2023 08h01 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming...
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
05 sept. 2023 08h00 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device...
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
14 août 2023 16h01 HE
|
Biora Therapeutics, Inc.
NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJet™ systemic oral delivery...